
Psoriasis Treatment
Description
Global Psoriasis Treatment Market to Reach US$32.4 Billion by 2030
The global market for Psoriasis Treatment estimated at US$22.3 Billion in the year 2024, is expected to reach US$32.4 Billion by 2030, growing at a CAGR of 6.5% over the analysis period 2024-2030. Interleukin Inhibitors, one of the segments analyzed in the report, is expected to record a 6.2% CAGR and reach US$11.8 Billion by the end of the analysis period. Growth in the Corticosteroids segment is estimated at 6.2% CAGR over the analysis period.
The U.S. Market is Estimated at US$5.8 Billion While China is Forecast to Grow at 10.7% CAGR
The Psoriasis Treatment market in the U.S. is estimated at US$5.8 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$7.8 Billion by the year 2030 trailing a CAGR of 10.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.7% and 6.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.3% CAGR.
Global Psoriasis Treatment Market - Key Trends & Drivers Summarized
Why Is the Psoriasis Treatment Market Gaining Prominence in Dermatology?
The psoriasis treatment market is gaining prominence in dermatology due to the increasing prevalence of psoriasis and the growing awareness of the condition among both patients and healthcare providers. Psoriasis is a chronic autoimmune disease characterized by the rapid growth of skin cells, leading to the formation of scaly patches, redness, and inflammation. With rising rates of obesity, metabolic syndrome, and other comorbidities that exacerbate psoriasis, the demand for effective treatment options is on the rise. As healthcare professionals become more attuned to the complexities of psoriasis and its impact on patients’ quality of life, there is a growing emphasis on developing and providing comprehensive treatment strategies that encompass both physical and psychological aspects.
One of the primary factors driving the growth of the psoriasis treatment market is the increasing availability of innovative therapies, including biologics, systemic medications, and topical treatments. Recent advancements in medical research have led to the development of targeted therapies that address specific pathways involved in the pathogenesis of psoriasis. Biologics, which are derived from living cells, have revolutionized the treatment landscape by offering effective and long-lasting solutions for moderate to severe psoriasis. These new therapies not only improve symptoms but also significantly enhance the overall quality of life for patients, driving the adoption of psoriasis treatments in clinical practice.
How Are Technological Advancements and Innovations Shaping the Psoriasis Treatment Market?
Technological advancements and innovations are significantly shaping the psoriasis treatment market by improving treatment options, enhancing patient monitoring, and personalizing care. One notable development is the evolution of biologic therapies, which target specific components of the immune system to reduce inflammation and skin cell proliferation. This class of medications has expanded treatment options for patients with moderate to severe psoriasis, providing more effective and tailored solutions. The introduction of oral biologics and biosimilars is also expected to increase access to treatment and reduce costs, further driving market growth.
Additionally, advancements in telemedicine and digital health technologies are transforming the way psoriasis is managed. Remote consultations and digital monitoring tools enable healthcare providers to assess patients’ conditions more efficiently, ensuring timely adjustments to treatment plans. Mobile applications and wearable devices that track symptoms and treatment adherence are becoming increasingly popular, empowering patients to take control of their condition. This trend towards personalized and remote care is enhancing the overall treatment experience for psoriasis patients and contributing to the growth of the market.
Moreover, ongoing research and development efforts in the field of psoriasis are leading to the discovery of new therapeutic targets and treatment modalities. Clinical trials are continuously exploring novel compounds and combination therapies that offer improved efficacy and safety profiles. The expansion of treatment options, including emerging therapies and novel drug formulations, is expected to enhance patient outcomes and satisfaction. This focus on innovation and research is a critical driver of growth in the psoriasis treatment market.
Furthermore, the increasing emphasis on holistic approaches to psoriasis management is shaping treatment strategies. Healthcare providers are recognizing the importance of addressing not only the physical symptoms but also the psychological and emotional impact of psoriasis. Integrating mental health support, lifestyle modifications, and complementary therapies into treatment plans is becoming more common. This comprehensive approach is driving the demand for multifaceted treatment solutions that can effectively address the complexities of psoriasis.
What Role Do Market Dynamics and Regulatory Trends Play in Shaping the Adoption of Psoriasis Treatments?
Market dynamics and regulatory trends play a crucial role in shaping the adoption of psoriasis treatments as industries respond to changing demands for effective therapies and compliance with regulations. The increasing prevalence of psoriasis is a key driver of the market, with millions of individuals affected worldwide. As healthcare providers become more aware of the need for effective treatment options, the adoption of advanced therapies is becoming essential. The ability to provide comprehensive treatment solutions that address the diverse needs of psoriasis patients is enhancing the market`s appeal and driving adoption.
Regulatory pressures surrounding drug approvals and safety standards are also influencing the adoption of psoriasis treatments. Regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), have established stringent guidelines for the approval and monitoring of psoriasis therapies. Compliance with these regulations is essential for manufacturers seeking to bring new products to market. The focus on rigorous testing and safety profiles enhances consumer confidence in available treatments, driving their adoption among healthcare providers and patients.
The competitive landscape within the dermatology and biopharmaceutical industries is another significant factor shaping the adoption of psoriasis treatments. Numerous manufacturers are entering the market, offering a wide range of treatment options tailored to specific patient needs. This competition is driving innovation and improvements in product quality, allowing manufacturers to meet the diverse requirements of different sectors. The focus on product differentiation, including the development of novel biologics and combination therapies, is enhancing the market presence of psoriasis treatments and contributing to their widespread adoption.
Consumer preferences for effective, reliable, and safe psoriasis treatments are also influencing adoption. As patients become more informed about their treatment options, there is a growing demand for therapies that provide fast and long-lasting results. Manufacturers are responding by developing treatments that offer improved efficacy and safety profiles, including options that minimize side effects. The ability to provide high-quality psoriasis treatments that meet the evolving needs of consumers is essential for manufacturers looking to gain a competitive edge in the market.
What Factors Are Driving the Growth of the Global Psoriasis Treatment Market?
The growth in the global psoriasis treatment market is driven by several factors, including the rising prevalence of psoriasis, advancements in therapeutic options, and ongoing research and development efforts. One of the primary growth drivers is the increasing awareness and diagnosis of psoriasis among healthcare professionals and patients. Improved understanding of the condition and its implications has led to more individuals seeking treatment, creating a larger patient base that requires effective therapeutic solutions.
The advancement of innovative therapies, particularly biologics and targeted treatments, is another key factor contributing to market growth. Biologics have transformed the treatment landscape for moderate to severe psoriasis, offering more effective and personalized solutions. The emergence of oral biologics and biosimilars is expected to further increase access to treatment and reduce costs, promoting the adoption of these therapies. The continuous development of new and improved treatment options is expected to fuel market growth as more effective therapies become available.
Ongoing research and development efforts in the field of dermatology are also supporting the growth of the psoriasis treatment market. Researchers are exploring new compounds and treatment modalities that target specific pathways involved in the pathogenesis of psoriasis. This focus on innovation is paving the way for the development of targeted therapies that can provide better outcomes for patients. The investment in R&D by biopharmaceutical companies is expected to lead to the introduction of novel treatment options, driving market expansion.
Moreover, the increasing focus on patient-centered care and holistic approaches to psoriasis management is creating new opportunities for the market. Healthcare providers are recognizing the importance of addressing the psychological and emotional impact of psoriasis, leading to integrated treatment approaches that include mental health support and lifestyle modifications. This trend towards comprehensive care is driving demand for multifaceted treatment solutions that can effectively address the complexities of psoriasis.
Additionally, the impact of the COVID-19 pandemic has heightened awareness of chronic health conditions, including psoriasis. As healthcare systems adapt to new challenges, there is a renewed focus on ensuring that patients receive the necessary care and support for their conditions. This emphasis on continuity of care is expected to drive the demand for psoriasis treatments, reinforcing the market`s growth trajectory.
As these factors converge, the global psoriasis treatment market is poised for robust growth, driven by advancements in therapeutic options, expanding patient awareness, and the increasing emphasis on improving health outcomes across various healthcare sectors.
SCOPE OF STUDY:The report analyzes the Psoriasis Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Drug Class (Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues, Other Drug Classes); Route of Administration (Parenteral, Oral, Topical)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.
Select Competitors (Total 44 Featured) -
- AbbVie, Inc.
- Amgen, Inc.
- Eli Lilly and Company
- Johnson & Johnson
- Merck & Co., Inc.
- Novartis International AG
- Pfizer, Inc.
We`re transforming market and competitive intelligence with validated expert content and AI tools.
Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.
The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.
Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.
Table of Contents
- I. METHODOLOGY
- II. EXECUTIVE SUMMARY
- 1. MARKET OVERVIEW
- Influencer Market Insights
- Tariff Impact on Global Supply Chain Patterns
- Psoriasis Treatment – Global Key Competitors Percentage Market Share in 2025 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
- 2. FOCUS ON SELECT PLAYERS
- 3. MARKET TRENDS & DRIVERS
- Rising Prevalence of Psoriasis and Psoriatic Arthritis Propels Growth in Psoriasis Treatment Market
- Increasing Adoption of Biologic Therapies in Moderate to Severe Psoriasis Expands Addressable Market
- Innovations in Topical Therapies Strengthen Business Case for Market Growth
- Increasing Use of Psoriasis Treatment in Dermatology and Specialty Clinics Expands Market Scope
- Technological Advancements in Oral and Injectable Biologics Propel Market Growth
- Case Overview: Growth in Adoption of Psoriasis Treatments in At-Home and Over-The-Counter Products Expands Market Reach
- Case Overview: Growth in Use of Psoriasis Treatment in Scalp and Nail Psoriasis Expands Market Reach
- Technological Advancements in Light and Laser-Based Psoriasis Therapies Propel Market Growth
- 4. GLOBAL MARKET PERSPECTIVE
- TABLE 1: World Psoriasis Treatment Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
- TABLE 2: World Recent Past, Current & Future Analysis for Psoriasis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 3: World Historic Review for Psoriasis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 4: World 15-Year Perspective for Psoriasis Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
- TABLE 5: World Recent Past, Current & Future Analysis for Interleukin Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 6: World Historic Review for Interleukin Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 7: World 15-Year Perspective for Interleukin Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 8: World Recent Past, Current & Future Analysis for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 9: World Historic Review for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 10: World 15-Year Perspective for Corticosteroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 11: World Recent Past, Current & Future Analysis for Tumor Necrosis Factor (TNF) Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 12: World Historic Review for Tumor Necrosis Factor (TNF) Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 13: World 15-Year Perspective for Tumor Necrosis Factor (TNF) Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 14: World Recent Past, Current & Future Analysis for Vitamin D Analogues by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 15: World Historic Review for Vitamin D Analogues by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 16: World 15-Year Perspective for Vitamin D Analogues by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 17: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 18: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 19: World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 20: World Recent Past, Current & Future Analysis for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 21: World Historic Review for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 22: World 15-Year Perspective for Parenteral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 23: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 24: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 25: World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- TABLE 26: World Recent Past, Current & Future Analysis for Topical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 27: World Historic Review for Topical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 28: World 15-Year Perspective for Topical by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
- III. MARKET ANALYSIS
- UNITED STATES
- Psoriasis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
- TABLE 29: USA Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 30: USA Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 31: USA 15-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 32: USA Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 33: USA Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 34: USA 15-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2015, 2025 & 2030
- CANADA
- TABLE 35: Canada Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 36: Canada Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 37: Canada 15-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 38: Canada Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 39: Canada Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 40: Canada 15-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2015, 2025 & 2030
- JAPAN
- Psoriasis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
- TABLE 41: Japan Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 42: Japan Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 43: Japan 15-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 44: Japan Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 45: Japan Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 46: Japan 15-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2015, 2025 & 2030
- CHINA
- Psoriasis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
- TABLE 47: China Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 48: China Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 49: China 15-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 50: China Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 51: China Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 52: China 15-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2015, 2025 & 2030
- EUROPE
- Psoriasis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
- TABLE 53: Europe Recent Past, Current & Future Analysis for Psoriasis Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 54: Europe Historic Review for Psoriasis Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 55: Europe 15-Year Perspective for Psoriasis Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
- TABLE 56: Europe Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 57: Europe Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 58: Europe 15-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 59: Europe Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 60: Europe Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 61: Europe 15-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2015, 2025 & 2030
- FRANCE
- Psoriasis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
- TABLE 62: France Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 63: France Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 64: France 15-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 65: France Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 66: France Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 67: France 15-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2015, 2025 & 2030
- GERMANY
- Psoriasis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
- TABLE 68: Germany Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 69: Germany Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 70: Germany 15-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 71: Germany Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 72: Germany Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 73: Germany 15-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2015, 2025 & 2030
- ITALY
- TABLE 74: Italy Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 75: Italy Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 76: Italy 15-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 77: Italy Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 78: Italy Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 79: Italy 15-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2015, 2025 & 2030
- UNITED KINGDOM
- Psoriasis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
- TABLE 80: UK Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 81: UK Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 82: UK 15-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 83: UK Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 84: UK Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 85: UK 15-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2015, 2025 & 2030
- SPAIN
- TABLE 86: Spain Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 87: Spain Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 88: Spain 15-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 89: Spain Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 90: Spain Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 91: Spain 15-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2015, 2025 & 2030
- RUSSIA
- TABLE 92: Russia Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 93: Russia Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 94: Russia 15-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 95: Russia Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 96: Russia Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 97: Russia 15-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2015, 2025 & 2030
- REST OF EUROPE
- TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 99: Rest of Europe Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 100: Rest of Europe 15-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 102: Rest of Europe Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 103: Rest of Europe 15-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2015, 2025 & 2030
- ASIA-PACIFIC
- Psoriasis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
- TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Psoriasis Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 105: Asia-Pacific Historic Review for Psoriasis Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 106: Asia-Pacific 15-Year Perspective for Psoriasis Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
- TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 108: Asia-Pacific Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 109: Asia-Pacific 15-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 111: Asia-Pacific Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 112: Asia-Pacific 15-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2015, 2025 & 2030
- AUSTRALIA
- Psoriasis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
- TABLE 113: Australia Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 114: Australia Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 115: Australia 15-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 116: Australia Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 117: Australia Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 118: Australia 15-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2015, 2025 & 2030
- INDIA
- Psoriasis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
- TABLE 119: India Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 120: India Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 121: India 15-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 122: India Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 123: India Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 124: India 15-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2015, 2025 & 2030
- SOUTH KOREA
- TABLE 125: South Korea Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 126: South Korea Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 127: South Korea 15-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 128: South Korea Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 129: South Korea Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 130: South Korea 15-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2015, 2025 & 2030
- REST OF ASIA-PACIFIC
- TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 132: Rest of Asia-Pacific Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 133: Rest of Asia-Pacific 15-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 135: Rest of Asia-Pacific Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 136: Rest of Asia-Pacific 15-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2015, 2025 & 2030
- LATIN AMERICA
- Psoriasis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
- TABLE 137: Latin America Recent Past, Current & Future Analysis for Psoriasis Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 138: Latin America Historic Review for Psoriasis Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 139: Latin America 15-Year Perspective for Psoriasis Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
- TABLE 140: Latin America Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 141: Latin America Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 142: Latin America 15-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 143: Latin America Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 144: Latin America Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 145: Latin America 15-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2015, 2025 & 2030
- ARGENTINA
- TABLE 146: Argentina Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 147: Argentina Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 148: Argentina 15-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 149: Argentina Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 150: Argentina Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 151: Argentina 15-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2015, 2025 & 2030
- BRAZIL
- TABLE 152: Brazil Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 153: Brazil Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 154: Brazil 15-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 155: Brazil Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 156: Brazil Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 157: Brazil 15-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2015, 2025 & 2030
- MEXICO
- TABLE 158: Mexico Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 159: Mexico Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 160: Mexico 15-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 161: Mexico Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 162: Mexico Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 163: Mexico 15-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2015, 2025 & 2030
- REST OF LATIN AMERICA
- TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 165: Rest of Latin America Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 166: Rest of Latin America 15-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 168: Rest of Latin America Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 169: Rest of Latin America 15-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2015, 2025 & 2030
- MIDDLE EAST
- Psoriasis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
- TABLE 170: Middle East Recent Past, Current & Future Analysis for Psoriasis Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 171: Middle East Historic Review for Psoriasis Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 172: Middle East 15-Year Perspective for Psoriasis Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
- TABLE 173: Middle East Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 174: Middle East Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 175: Middle East 15-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 176: Middle East Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 177: Middle East Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 178: Middle East 15-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2015, 2025 & 2030
- IRAN
- TABLE 179: Iran Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 180: Iran Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 181: Iran 15-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 182: Iran Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 183: Iran Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 184: Iran 15-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2015, 2025 & 2030
- ISRAEL
- TABLE 185: Israel Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 186: Israel Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 187: Israel 15-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 188: Israel Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 189: Israel Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 190: Israel 15-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2015, 2025 & 2030
- SAUDI ARABIA
- TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 192: Saudi Arabia Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 193: Saudi Arabia 15-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 195: Saudi Arabia Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 196: Saudi Arabia 15-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2015, 2025 & 2030
- UNITED ARAB EMIRATES
- TABLE 197: UAE Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 198: UAE Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 199: UAE 15-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 200: UAE Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 201: UAE Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 202: UAE 15-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2015, 2025 & 2030
- REST OF MIDDLE EAST
- TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 204: Rest of Middle East Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 205: Rest of Middle East 15-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 207: Rest of Middle East Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 208: Rest of Middle East 15-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2015, 2025 & 2030
- AFRICA
- Psoriasis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
- TABLE 209: Africa Recent Past, Current & Future Analysis for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 210: Africa Historic Review for Psoriasis Treatment by Drug Class - Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 211: Africa 15-Year Perspective for Psoriasis Treatment by Drug Class - Percentage Breakdown of Value Sales for Interleukin Inhibitors, Corticosteroids, Tumor Necrosis Factor (TNF) Inhibitors, Vitamin D Analogues and Other Drug Classes for the Years 2015, 2025 & 2030
- TABLE 212: Africa Recent Past, Current & Future Analysis for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 213: Africa Historic Review for Psoriasis Treatment by Route Of Administration - Parenteral, Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
- TABLE 214: Africa 15-Year Perspective for Psoriasis Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Topical for the Years 2015, 2025 & 2030
- IV. COMPETITION
Pricing
Currency Rates